Marina Biotech is a clinical stage biotechnology company focused on development and commercialization of therapeutic products for rare diseases based on RNA interference (RNAi). The company is developing proprietary single and double-stranded nucleic acid therapeutics including siRNAs, microRNA mimics, antagomirs, and antisense compounds intended to trigger various RNA-based mechanisms of action including RNA interference, microRNA replacement therapy, microRNA inhibition and mRNA translational inhibition, respectively.